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Abstract
Background: Mast cells (MCs) are implicated in inflammation and tissue remodeling. Accumulation of lung MCs is
described in pulmonary hypertension (PH); however, whether MC degranulation and c-kit, a tyrosine kinase
receptor critically involved in MC biology, contribute to the pathogenesis and progression of PH has not been fully
explored.
Methods: Pulmonary MCs of idiopathic pulmonary arterial hypertension (IPAH) patients and monocrotaline-
injected rats (MCT-rats) were examined by histochemistry and morphometry. Effects of the specific c-kit inhibitor
PLX and MC stabilizer cromolyn sodium salt (CSS) were investigated in MCT-rats both by the preventive and
therapeutic approaches. Hemodynamic and right ventricular hypertrophy measurements, pulmonary vascular
morphometry and analysis of pulmonary MC localization/counts/activation were performed in animal model
studies.
Results: There was a prevalence of pulmonary MCs in IPAH patients and MCT-rats as compared to the donors and
healthy rats, respectively. Notably, the perivascular MCs were increased and a majority of them were degranulated
in lungs of IPAH patients and MCT-rats (p < 0.05 versus donor and control, respectively). In MCT-rats, the
pharmacological inhibitions of MC degranulation and c-kit with CSS and PLX, respectively by a preventive
approach (treatment from day 1 to 21 of MCT-injection) significantly attenuated right ventricular systolic pressure
(RVSP) and right ventricular hypertrophy (RVH). Moreover, vascular remodeling, as evident from the significantly
decreased muscularization and medial wall thickness of distal pulmonary vessels, was improved. However,
treatments with CSS and PLX by a therapeutic approach (from day 21 to 35 of MCT-injection) neither improved
hemodynamics and RVH nor vascular remodeling.
Conclusions: The accumulation and activation of perivascular MCs in the lungs are the histopathological features
present in clinical (IPAH patients) and experimental (MCT-rats) PH. Moreover, the accumulation and activation of
MCs in the lungs contribute to the development of PH in MCT-rats. Our findings reveal an important
pathophysiological insight into the role of MCs in the pathogenesis of PH in MCT- rats.
Background
A growing body of studies in recent years implicates
inflammation and dysregulated growth factor signaling in
the pathogenesis of pulmonary arterial hypertension
(PAH) [1]. Among the growth factors, platelet derived
growth factor (PDGF) has been extensively investigated
[2,3]. We have demonstrated that reversal of experimental
pulmonary hypertension (PH) and vascular remodeling by
imatinib is associated with the inhibition of PDGF recep-
tor (PDGFR), a member of receptor tyrosine kinase (RTK)
family [3]. Subsequently, Wang et al. have found that c-kit
play an important role in systemic vascular remodeling
[4,5]. As imatinib is also a potent inhibitor of the RTK, c-
kit [6], the data indicate that c-kit may potentially contri-
bute to the pathological remodeling of pulmonary vessels.
It is well documented that hematopoetic stem and
progenitor cells express c-kit; however, c-kit expression
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is downregulated on maturation of all haemopoietic
lineages, except mast cells (MCs) that retain high levels
of expression [7]. In general, c-kit activation initiates
cellular responses such as chemotaxis, proliferation, dif-
ferentiation and survival [8]. Moreover, activation of c-
kit by its ligand, the stem cell factor (SCF)/MC growth
factor is associated with MC development, proliferation,
migration and degranulation [9,10]. Therefore, c-kit is
described as a pharmacological target for therapy of
multiple pathological conditions linked to MCs[11]. MC
activation and degranulation have been attributed a role
in airway and cardiac remodeling [12-15]. Regarding
pulmonary vascular pathology, an increased lung MCs
has been reported in plexogenic pulmonary arteriopathy
[16], pulmonary hypertension [17] and congenital heart
diseases associated with early pulmonary vascular dis-
eases [18]. Moreover, MCs/c-kit expressing cells have
been localized along the periphery/adventitial layer of
remodelled pulmonary vessels in experimental PH
[19-21]. Recently, MC degranulation has been impli-
cated both in the development of pulmonary vascular
remodeling in chronic hypoxic rats and in the regression
of the remodeling upon bringing them back to normoxia
[22,23]. Activated MCs produce several mediators
including the biogenic amine serotonin, the cytokines
interleukin (IL)-6 and IL-13, and the serine proteases
chymase and tryptase that are capable of activating
matrix metalloproteases (MMPs) [9]. The implication of
serotonin, IL-6, IL-13 and MMPs in PH pathogenesis
[1,24-26] provides a potential mechanistic rationale to
the hypothesis that MCs may be involved in the patho-
genesis of PH and pulmonary vascular remodeling.
However, a systematic examination of pulmonary MCs
in clinical and experimental PH and an elucidation of
the role of MCs in animal model of progressive PH are
still missing. In this study, we therefore investigated the
lung tissues from idiopathic PAH (IPAH) patients and
monocrotaline (MCT)-injected rats to determine total
and perivascular MC count, and the degranulation of
the perivascular MCs. Furthermore, we investigated the
effects of the pharmacologic inhibitions of c-kit and MC
degranulation on hemodynamics, right ventricular
hypertrophy and pulmonary vascular remodeling in
MCT-induced PH in rat.
Methods
Animals and experimental design
Adult male Sprague-Dawley (SD) rats were obtained
from Charles River Laboratories, Germany. All studies
were approved by the local authority (Regierungspräsi-
dium Gießen) and were performed according to the
guidelines of the University of Giessen. PH was induced
in rats by MCT injection as described [3]. Rats were
randomized and treated daily with the selective c-kit
inhibitor (PLX, kindly provided by Plexxikon Inc.). PLX
was freshly prepared in 5% DMSO, 1% methylcellulose
and administered by oral gavage at the dose of 50 mg/
kg body weight. Another group of rats received the MC
stabilizer Cromolyn sodium salt (CSS, Sigma-Aldrich)
daily through intra-peritoneal injection. CSS was freshly
prepared in saline and given at the dose of 40 mg/kg
body weight. Rats in the placebo groups received respec-
tive vehicles only. In a preventive approach, pharmaco-
logical inhibition of c-kit or MC degranulation was
initiated from day 1 till day 21 of MCT injection. In the
therapeutic approach, the inhibition was performed
from day 21 till day 35 of MCT injection when the dis-
ease is established or already rapidly progressing.
Hemodynamic and Right Ventricular Hypertrophy (RVH)
Measurements
Hemodynamic and RVH measurements were performed
as previously reported [27]. For monitoring hemody-
namics, rats were anesthetized, tracheotomized and arti-
ficially ventilated at a constant frequency of 60 breaths
per minute. Inspiratory oxygen (FIO2) was set at 0.5,
and a positive end expiratory pressure of 1.0 cm H2O
was used. The left carotid artery was isolated and can-
nulated with a polyethylene cannula connected to a
fluid-filled force transducer and the systemic arterial
pressure (SAP) was measured. A catheter was inserted
through the right jugular vein into the right ventricle to
measure right ventricular systolic pressure (RVSP). The
animals were ex-sanguinated and the lungs were flushed
with sterile saline to get rid of blood. The left lung was
fixed for histology in 3.5% neutral buffered formalin and
the right lung was snap frozen in liquid nitrogen. The
heart was isolated and dissected under microscope. The
right ventricular wall was separated from the left ventri-
cular wall and ventricular septum. Dry weight of the
right ventricle, free left ventricular wall and ventricular
septum was determined. Right ventricular hypertrophy
was expressed as the ratio of weight of the right ventri-
cular wall (RV) and that of the free left ventricular wall
and ventricular septum (LV+S).
Histology and Pulmonary Vascular Morphometry
Lung histology and vascular morphometry were per-
formed as described [27]. The formalin-fixed and paraf-
fin-embedded lung tissues were subject to sectioning to
yield 3 μm thick sections. Elastica staining was per-
formed according to common histopathological proce-
dures. The degree of muscularization of small peripheral
pulmonary arteries was assessed by double-staining the
sections with an anti-a-smooth muscle actin antibody
(dilution 1:900, clone 1A4, Sigma, Saint Louis, Missouri)
and anti-human von Willebrand factor antibody (vWF,
dilution 1:900, Dako, Germany) followed by analysis of
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the vessels using a computerized morphometric analysis
system (QWin; Leica, Germany) to determine the degree
of pulmonary artery muscularization. In each rat, 80 to
100 intra-acinar arteries (20 to 50 μm diameter) were
categorized as muscular, partially muscular, or non-
muscular. In addition, arteries of the same size were
analyzed to determine the medial wall thickness as pre-
viously described [27]. All analyses were done in a
blinded fashion.
Patient characterization
Human lung tissues were obtained from donors and
patients with IPAH undergoing lung transplantation.
After explantation, lung tissues were formalin-fixed and
paraffin-embedded according to common tissue proces-
sing protocol. Written informed consent was obtained
from each individual patient or the patient’s next kin.
Among the IPAH patients six were male and four were
female. They had mean pulmonary artery pressure
(mPAP in mmHg) of 74.10 ± 9.8 (mean ± SEM, n = 10)
and cardiac index (CI in l/min/m2) of 2.09 ± 0.22 (mean
± SEM, n = 8). The patients had undergone treatment
for PAH with the currently available options namely,
prostacyclin analogues, PDE5 inhibitor and endothelin
receptor antagonists. The study protocol was approved
by the ethics committee of the University of Giessen
that conforms to the principles outlined in the Declara-
tion of Helsinki.
Histology and mast cell (MC) counting
In addition to the paraffin-embedded lung tissues from
IPAH patients and donors, the lung tissues of rats from
the interventional studies were included in the histology
and subsequent MC analysis. Moreover, lung tissues
from MCT-rats that received imatinib (100 mg/kg bw/
day through oral gavage) by a therapeutic approach were
included. To identify MCs toluidine blue staining was
performed using standard protocols. Briefly, paraffin-
embedded tissue sections were dewaxed, rehydrated and
incubated with 0.05% w/v toluidine blue for 2-3 minutes.
MC density was quantified by counting the number of
toluidine blue-positive MCs. MC numbers and the extent
of their degranulation were assessed manually as
described in the literature [28,29] with modification.
Total MCs were counted throughout section in each
lung under light microscope. In addition, perivascular
MCs (of different vessel sizes such as 20-50, 50-150 and
>150 μm) were counted. Moreover, perivascular MCs
were categorized into granulated and degranulated based
on the extrusion of secretory granules (i.e. intact MCs
with dense cytoplasm are granulated, whereas degranu-
lated MCs have light cytoplasm with empty spots due to
the discharge of secretory granules). Furthermore, an
index of granulation (IOG) [(number of granulated MC/
number of degranulated MC)] was determined. The IOG
was expressed in percentage assuming that the average
IOG in donors and healthy rats were 100%. The MC ana-
lysis was done by independent investigators. The meth-
ods and results of the MC analysis have been presented
in the form of an abstract [30].
Data analysis
Data were expressed as mean ± SEM. Comparison
among the experimental groups were done by one way
analysis of variance (ANOVA) and subsequent New-
man-Keuls test. Unpaired T-test was used to compare
MC count. A value of P < 0.05 was considered as statis-
tically significant. The number of animals/tissue samples
used in each experiment/analysis has been mentioned in
the figure legends.
Results
Prevalence and degranulation of MCs in the lungs of
IPAH patients
Toluidine blue staining showed that MCs were scattered
throughout the lung tissues including peribronchial, sep-
tal and perivascular areas (Figure 1A). We counted the
MCs and found that MC population was about 8 fold
higher in IPAH patients as compared to the donors
(Figure 1B). There was a preponderance of perivascular
MCs in IPAH lungs (p < 0.05 versus donor lungs).
Moreover, about 3 and 4 fold increases in MCs were
observed around resistance (20-50 and 50-150 μm in
diameter) and the larger (> 150 μm) vessels, respectively
in the lungs of IPAH patients as compared to the
donors (Figure 1C). We categorized perivascular MCs as
granulated and degranulated (Figure 1D) and calculated
the index of granulation (IOG) to examine their activa-
tion status. Interestingly, there was a 5.7 fold decrease
of IOG in IPAH lungs (Figure 1E), suggesting that
majority of the perivascular MCs were degranulated/
activated.
Prevalence and degranulation of MCs in the lungs of
MCT-rats
As in clinical PH, pulmonary MC count was increased
in MCT-rats (p < 0.05 versus healthy rats) and they
were distributed throughout the lungs including peri-
bronchial, perivascular and septal areas (Figure 2A, 2B).
Perivascular MCs, the MC population of interest, was
prevalent in MCT-rats (p < 0.05 versus healthy rats).
Interestingly, there was about 9-fold increase in the
number of MCs around the intra-acinar vessels (20-50
μm in diameter), whereas about 5- and 2-fold increases
were found around the pre-acinar vessels (50-150 and
>150 μm, respectively) in MCT-rats as compared to
healthy rats (Figure 2C). As observed in the IPAH lungs,
majority of the perivascular MCs was activated as
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evident from 6.3 fold decrease of their IOG in MCT-rats
as compared to healthy rats (Figure 2D).
Effects of inhibition of c-kit and MC degranulation in
MCT-rats: Preventive approach
Hemodynamics, right ventricular hypertrophy and
pulmonary vascular remodeling
We then investigated if inhibition of c-kit by PLX and of
MC degranulation by CSS had any modulating effects
on the development of MCT-induced PH and vascular
remodeling. We found that MCT-rats receiving placebo
developed significantly higher right ventricular systolic
pressure (RVSP) and right ventricular hypertrophy (RV/
(LV+S)) as compared to healthy rats, whereas rats trea-
ted with PLX and CSS revealed significantly reduced
RVSP and RV/(LV+S) as compared to placebo group
(Figure 3A, 3B). No significant change was observed in
systemic arterial pressure (SAP) (Figure 3C).
An increased muscularization and medial wall thick-
ness of distal pulmonary vessels was present in MCT-
rats receiving placebo as reflected from the enhanced
immunoreactivity for a-smooth muscle cell (SMC) actin
(not shown) and elastica staining (Figure 4A). Vascular
morphometry revealed an increased fully muscularized
vessels accompanied by decreased non-muscularized
vessels in placebo group (P < 0.05 versus healthy rats).
In rats receiving PLX and CSS, the percentage of fully
muscularized vessels was reduced (P < 0.05 versus pla-
cebo) (Figure 4B). Moreover, the medial wall thickness
was increased in the placebo group (p < 0.05 versus
healthy rats). Corroborating the decreased fully muscu-
larized vessels, medial wall thickness was significantly
reduced in rats receiving PLX and CSS (Figure 4C).
MC count and degranulation
We investigated the effects of treatments on pulmonary
MCs. The number of MCs in MCT-rats receiving pla-
cebo was increased as compared with the healthy rats,
whereas there was a decrease of MCs in MCT-rats trea-
ted with PLX and CSS (p < 0.05 versus placebo) (Figure
5A). The perivascular MCs were then analyzed and their
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Figure 1 Prevalence of pulmonary MCs in IPAH patients. Lung tissues from donors and IPAH patients were stained with toluidine blue (TB).
The arrow indicates the positive signal (purple/violet stain) for the TB-stained MCs. (A) Representative photomicrographs of lung sections from
donor (a) and patients (b) are shown. (B) Total and (C) perivascular MC count of different vessel size are given. (D) Perivascular MCs were further
analyzed to identify granulated (a) and degranulated (b) MCs, and an index of granulation (IOG) was determined. (E) IOG (in %) is shown. Each
bar represents Mean ± SEM (n = 10-15). *p < 0.05 versus donor/corresponding vessels of donor. Scale = 20 μm.
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activation/degranulation status was determined. We
found that the IOG of perivascular MCs was signifi-
cantly decreased in placebo rats as compared to healthy
rats. Treatment with PLX and CSS resulted in an
increase in IOG (p < 0.05 versus placebo) (Figure 5B).
Effects of inhibition of c-kit and MC degranulation in
MCT-rats: Therapeutic approach
Hemodynamics, right ventricular hypertrophy and
pulmonary vascular remodeling
The findings of the preventive study prompted us to
investigate the effects of inhibition of c-kit and MC
degranulation by a therapeutic approach. Surprisingly,
we did not find any significant reduction of RVSP and
RV/(LV+S) in MCT-rats treated with PLX and CSS as
compared to placebo rats (Figure 6A, 6B and 6C). More-
over, the treatment did not impair the progression of
pulmonary vascular remodeling as evident from the
comparable degree of muscularization and medial wall
thickness of distal pulmonary vessels in treated versus
placebo rats (Figure 6D and 6E).
MC count and degranulation
We analyzed pulmonary MCs including lung tissues
obtained from imatinib-treated MCT-rats. A massive
increase of MCs was found in MCT-rats receiving pla-
cebo, whereas treatments with PLX, CSS and imatinib
significantly reduced MC counts (Figure 7A). Analysis
of perivascular MCs revealed that the IOG was signifi-
cantly decreased in placebo rats (P < 0.05 versus healthy
rats) and the treatments with PLX, CSS and imatinib
significantly increased the IOG as compared to placebo
(Figure 7B).
Discussion
For more than a decade, pulmonary MCs are known to
accumulate in primary plexogenic pulmonary arteriopa-
thy (PPA) [16], pulmonary hypertension [17] and conge-
nital heart diseases associated with early pulmonary
vascular diseases [18]; however, quantitative data on pul-
monary MCs have been lacking in the PH patients. In
line with the literature, we found higher MC count, sug-
gesting that MCs were prevalent in the lungs of IPAH
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Figure 2 Prevalence of pulmonary MCs in MCT-rats. Lung tissue from healthy and MCT-rats (that received single injection of saline and
monocrotaline, respectively) were stained with toluidine blue (TB). The arrow indicates the positive signal (purple/violet stain) for MCs. (A)
Representative photomicrographs of healthy (a) and MCT-injected (b) rat lungs are shown. (B) Total and (C) perivascular MC count of different
vessel sizes are given. An IOG was determined for perivascular MCs and (D) IOG (in %) is shown. Each bar represents Mean ± SEM (n = 10). *p <
0.05 versus healthy rats/corresponding vessels of healthy rats. Scale = 20 μm.
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patients. Additionally, analysis of the perivascular MCs
revealed that MC count was significantly higher and
majority of them were degranulated in patients. As in
IPAH patients, increased pulmonary MCs were observed
in MCT-rats. The MC count was significantly higher
along the perivascular space and in particular, a remark-
able increase was observed around intra-acinar vessels.
Corroborating our findings, Miyata et al. have described
more MCs around the vessels in MCT-rats [31]. More-
over, MCs are localized around the pulmonary vessels in
rats with severe PH [21]. We extended these findings
and demonstrated that majority of the perivascular MCs
were degranulated in the lungs of MCT-rats. The pre-
ponderance of the degranulated MCs may be attributa-
ble to the potent toxic effects of monocrotaline on the
pulmonary vessels resulting in radical tissue injury and
inflammatory process [32,33] and increased pulmonary
vascular pressure/resistance [34]. Taken together, the
findings suggest that a prevalence of degranulated peri-
vascular MCs is common to clinical and experimental
PH.
Activation of the receptor c-kit is involved in MC
development, proliferation, migration and degranulation,
and several pathological conditions related to MC disor-
ders are associated with c-kit dysregulation [9,35-37].
We therefore targeted c-kit and found that the selective
inhibition of c-kit by a preventive approach improved
PH, RVH and pulmonary vascular remodeling in MCT-
rats; furthermore, there was significant reduction in MC
accumulation and perivascular MC degranulation in the
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Figure 7 Effects of inhibiting c-kit and MC degranulation on pulmonary MCs in rats with MCT- induced PH. Rats were treated with
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lungs. The findings suggest that c-kit is involved in the
development of PH in MCT-rats by promoting perivas-
cular MC accumulation and degranulation in the lungs.
In agreement with our data, Wang et al. demonstrate
that early intervention with imatinib, a tyrosine kinase
inhibitor that beside other RTKs also targets c-kit
results in a marked reduction in intimal hyperplasia [4].
Moreover, imatinib treatment from later phase of hyper-
plasia does not yield beneficial effects [4]. Consistent
with the data of Wang et al., we observed no beneficial
effects of c-kit inhibition by a therapeutic approach in
MCT-rats. On the other hand, multikinase inhibitors
such as imatinib and sorafenib provide therapeutic bene-
fit in experimental PH [3,38], suggesting that inhibitions
of other RTKs like PDGFR or Raf may be attributable to
the observed benefits. Indeed, we have previously
demonstrated that imatinib provides therapeutic benefit
in experimental PH through an inhibition of PDGFR
activation [3]. However, whether imatinib has any effects
on pulmonary MCs has yet been undetermined. We
therefore analyzed lung tissues from MCT-rats treated
with imatinib and found that MC accumulation and
perivascular MC degranulation were almost abrogated.
The effects of imatinib on pulmonary MCs may be attri-
butable to the inhibition of c-kit and to an interference
of the interaction of MCs with other factors [39-42]. It
is not unlikely that the therapeutic benefits of imatinib
in experimental PH may be attributed to its potent
effects on MCs, in addition to its effects on vascular
cells through inhibition of PDGF signaling. However, we
currently do not have evidence to delineate the thera-
peutic benefits associated with the effects of imatinib on
pulmonary MCs.
As c-kit is also expressed by hematopoetic stem/pro-
genitor cells, the effects of its inhibition may not neces-
sarily be due to an interference with MCs [43]. On the
other hand, MC activation and degranulation release
various mediators including serotonin, cytokines (e.g.,
IL-6, IL-13), serine proteases (e.g., chymase) and matrix
metalloproteases (e.g., MMP 13) [9,44]. Notably, these
mediators play a role in the pathogenesis of PH and pul-
monary vascular remodeling [1,17,24,25,44]. We there-
fore selectively inhibited MC degranulation and found
that the development of PH, RVH and pulmonary vas-
cular remodeling in MCT-rats was significantly
impaired. There was a significant inhibition of perivas-
cular MC degranulation and reduction of pulmonary
MC count, suggesting that the amelioration of PH may
be associated with the reduced accumulation of MCs
and prevention of their mediators from being released.
Moreover, the findings suggest that the MC activation
and accumulation are mutually enhanced in the process
of PH pathogenesis. Corroborating our findings, Hoff-
mann et al. showed that prevention of MC
degranulation attenuated the PH and vascular remodel-
ing in rats with left heart disease and in MCT-rats [34].
The study, however, did not investigate the effects by a
therapeutic strategy. In the current study, we inhibited
the MC degranulation by a therapeutic approach, but
did not observe beneficial effects, suggesting that MCs
may no longer have modulating effects on the pathogen-
esis after the PH is established in MCT-rats. Although
surprising at first glance, it should be noted that the
intervention was started after the PH was established.
The pathogenesis at this advanced stage may be poten-
tially self-perpetuating owing to the involvement of a
host of redundant factors. Such factors include various
growth factors, proteases and inflammatory mediators
that have been incriminated in the pathogenesis of PH
[1,3,21,45]. In line with our findings, Banasova et al.
demonstrate that MCs play a role in the development of
PH in hypoxic rats [22]. The authors observe that inhi-
bition of MC degranulation at an early stage of hypoxia
attenuates the development of PH while it is without
effects if administered at a later stage. In contrast, Mun-
gal did not observe a beneficial effect on the right ven-
tricular hypertrophy in chronic hypoxic rats by using
disodium cromoglycate (DSCG) [46]. This contrasting
observation may be attributable to the lower dose of
DSCG (10 mg/kg BW) used in his study. Taken
together, it may be deduced that an inhibition of MC
degranulation impairs the development but does not
affect the established PH in rats irrespective of the sti-
muli (hypoxia/monocrotaline). Our pharmacological
inhibition studies (c-kit and MC degranulation) are con-
sistent and thus substantiate the findings that an inter-
ference with MC dysfunctions impairs the development
of MCT-induced PH. Moreover, our findings reveal a
hitherto unrecognized role of MCs in the early develop-
ment versus late established stages of pathogenesis of
MCT-induced PH in rats.
We performed additional studies on mice that were
genetically deficient in MCs [47] (c-kit deficient W/Wv
and stem cell factor deficient Sl/Sld mice). W/Wv mice
have a primary defect in hematopoietic stem cells,
whereas Sl/Sld mice have defective tissue microenviron-
ment [47,48]. We exposed the mice to chronic hypoxia
and found that both W/Wv and Sl/Sld mice developed
PH, RVH and vascular remodeling (Additional file
1Methods and Results; Additional file 2, Figure S1; Addi-
tional file 3, Figure S2). Our findings are in line with
previous findings from mouse model of hypoxic PH [49]
but not from rat models of PH [22,34]. The contrasting
findings may be attributable to the relative paucity of
MCs in the normal mouse than rats. Indeed, a wide
variability in the pulmonary MC numbers has been
reported among various species [50]. This raises the
issue of the relevance of animal models to clinical
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situation in humans. The chronic hypoxic mice develop
mild PH and vascular remodeling as compared to the
MCT-rats, which show several features of human PH
such as inflammation, media hypertrophy, adventitial
thickening, and progressive increase in pulmonary arter-
ial pressure and right heart failure. We now report that
the accumulation and increased degranulation of peri-
vascular MCs in the lungs are common to MCT-rats
and IPAH patients. The limitation of our findings is that
targeting c-kit and MC degranulation do not provide
therapeutic benefits. However, future in vitro and in
vivo studies designed to elucidate MC-associated patho-
mechanism in pulmonary vascular remodeling at the
level of cellular interaction and intracellular signaling
may unravel novel potential targets for PH treatment.
In conclusion, the accumulation and activation of
perivascular MCs are the histopathological features pre-
sent in the lungs of IPAH patients and MCT-rats. This,
to our knowledge, is the first study that reports the
quantitative assessment of pulmonary MCs in clinical
and experimental PH. Moreover, the accumulation and
activation of MCs in the lungs contribute to the devel-
opment of PH in MCT-rats. This study offers important
pathophysiological insights into the role of MCs in the
pathogenesis of PH in MCT- rats.
Additional material
Additional file 1: Methods, results and figure legends. Effects of mast
cell (MC) deficiency on chronic hypoxia-induced PH in mice.
Additional file 2: Figure S1. Effects of c-kit/MC deficiency on chronic
hypoxia-induced PH.
Additional file 3: Figure S2. Effects of stem cell factor/MC deficiency on
chronic hypoxia-induced PH.
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